Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.39 Million USD | 18.91% |
| 2022 | 4.52 Million USD | 45.33% |
| 2021 | 3.11 Million USD | 5576.98% |
| 2020 | -56.79 Thousand USD | -110.11% |
| 2019 | 561.62 Thousand USD | 3.24% |
| 2018 | 543.97 Thousand USD | 107.72% |
| 2017 | 261.87 Thousand USD | 300.87% |
| 2016 | 65.32 Thousand USD | 4.13% |
| 2015 | 62.73 Thousand USD | 229.29% |
| 2014 | 19.05 Thousand USD | -79.17% |
| 2013 | 91.47 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 36.34 Thousand USD | -96.92% |
| 2024 Q1 | 1.17 Million USD | -12.33% |
| 2023 Q3 | 1.46 Million USD | 16.89% |
| 2023 FY | 5.37 Million USD | 18.91% |
| 2023 Q1 | 1.33 Million USD | 42.63% |
| 2023 Q2 | 1.24 Million USD | -6.44% |
| 2023 Q4 | 1.34 Million USD | -7.91% |
| 2022 Q2 | 1.39 Million USD | 27.64% |
| 2022 Q1 | 1.09 Million USD | 3.08% |
| 2022 FY | 4.52 Million USD | 45.33% |
| 2022 Q4 | 936.2 Thousand USD | -13.97% |
| 2022 Q3 | 1.08 Million USD | -22.25% |
| 2021 FY | 3.11 Million USD | 5576.98% |
| 2021 Q2 | 558.5 Thousand USD | 456.93% |
| 2021 Q1 | 100.28 Thousand USD | 111.41% |
| 2021 Q3 | 1.38 Million USD | 148.53% |
| 2021 Q4 | 1.06 Million USD | -23.37% |
| 2020 Q1 | 136.61 Thousand USD | -13.81% |
| 2020 Q3 | 139.07 Thousand USD | -74.54% |
| 2020 Q4 | -878.81 Thousand USD | -731.9% |
| 2020 FY | -56.79 Thousand USD | -110.11% |
| 2020 Q2 | 546.33 Thousand USD | 299.9% |
| 2019 Q2 | 163.91 Thousand USD | 9.98% |
| 2019 Q3 | 90.16 Thousand USD | -44.99% |
| 2019 Q4 | 158.5 Thousand USD | 75.79% |
| 2019 FY | 561.62 Thousand USD | 3.24% |
| 2019 Q1 | 149.04 Thousand USD | 16.09% |
| 2018 Q4 | 128.38 Thousand USD | -23.95% |
| 2018 Q3 | 168.82 Thousand USD | 26.93% |
| 2018 Q2 | 133 Thousand USD | 16.91% |
| 2018 Q1 | 113.76 Thousand USD | -31.34% |
| 2018 FY | 543.97 Thousand USD | 107.72% |
| 2017 FY | 261.87 Thousand USD | 300.87% |
| 2017 Q4 | 165.68 Thousand USD | 408.19% |
| 2017 Q3 | 32.6 Thousand USD | 7.66% |
| 2017 Q2 | 30.28 Thousand USD | -9.08% |
| 2017 Q1 | 33.3 Thousand USD | 43.2% |
| 2016 Q1 | 14.88 Thousand USD | 16.07% |
| 2016 FY | 65.32 Thousand USD | 4.13% |
| 2016 Q4 | 23.25 Thousand USD | 117.78% |
| 2016 Q3 | 10.68 Thousand USD | -35.28% |
| 2016 Q2 | 16.5 Thousand USD | 10.84% |
| 2015 FY | 62.73 Thousand USD | 229.29% |
| 2015 Q3 | 13.69 Thousand USD | -24.4% |
| 2015 Q2 | 18.11 Thousand USD | -0.01% |
| 2015 Q1 | 18.11 Thousand USD | 138.3% |
| 2015 Q4 | 12.82 Thousand USD | -6.32% |
| 2014 Q4 | 7600.00 USD | 0.0% |
| 2014 FY | 19.05 Thousand USD | -79.17% |
| 2013 FY | 91.47 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bright Green Corporation | -237.01 Thousand USD | 2376.014% |
| BioQuest Corp. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 17.716% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 97.566% |
| GSRX Industries Inc. | - USD | -Infinity% |
| High Sierra Technologies, Inc. | -56.39 Thousand USD | 9665.934% |
| Instadose Pharma Corp. | - USD | -Infinity% |